Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
7.75
+0.11 (1.44%)
Aug 6, 2026, 4:00 PM EDT - Market closed
Kyverna Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 32.19 | 124.09 | 96.62 | 34.65 | 37.74 | 76.07 |
Short-Term Investments | 204.25 | 155.16 | 189.36 | 22.9 | 13.59 | - |
Cash & Short-Term Investments | 236.45 | 279.25 | 285.98 | 57.54 | 51.32 | 76.07 |
Cash Growth | -2.56% | -2.35% | 396.98% | 12.12% | -32.53% | - |
Other Current Assets | 5.28 | 3.7 | 4.62 | 3.12 | 1.93 | 1.02 |
Total Current Assets | 241.73 | 282.95 | 290.6 | 60.66 | 53.25 | 77.09 |
Net Property, Plant & Equipment | 9.73 | 5.42 | 10.66 | 10.61 | 12.44 | 7.81 |
Other Long-Term Assets | 5.57 | 5.45 | 3.39 | 3.92 | 1.23 | 0.59 |
Total Assets | 257.02 | 293.83 | 304.65 | 75.2 | 66.92 | 85.49 |
Accounts Payable | 11.6 | 5.31 | 4.62 | 4.36 | 1.45 | 0.77 |
Accrued Expenses | 16.09 | 27.21 | 25.19 | 12.58 | 8.23 | 8.34 |
Current Portion of Leases | 1.99 | 3.97 | 3.94 | 2.92 | 2.28 | 0.81 |
Unearned Revenue | - | - | - | - | - | 6 |
Total Current Liabilities | 29.67 | 36.49 | 33.76 | 19.86 | 11.95 | 15.93 |
Long-Term Debt | 24.81 | 24.74 | - | - | - | - |
Long-Term Leases | 6.96 | 0.32 | 4.3 | 6.16 | 8.29 | 4.74 |
Other Long-Term Liabilities | - | - | - | - | 0.01 | 2.35 |
Total Long-Term Liabilities | 31.77 | 25.06 | 4.3 | 6.16 | 8.29 | 7.09 |
Total Liabilities | 61.44 | 61.55 | 38.06 | 26.02 | 20.25 | 23.02 |
Common Stock | 0 | 0 | - | - | - | - |
Additional Paid-in Capital | 660.23 | 657.01 | 530 | 4.64 | 1.71 | 0.53 |
Accumulated Other Comprehensive Income | -0.1 | 0.1 | 0.11 | 0 | -0.03 | - |
Retained Earnings | -464.56 | -424.83 | -263.52 | -136.04 | -75.68 | -46.78 |
Total Common Shareholders' Equity | 195.58 | 232.28 | 266.59 | -131.4 | -74 | -46.25 |
Minority Interest | - | - | - | 180.57 | 120.67 | 108.72 |
Shareholders' Equity | 195.58 | 232.28 | 266.59 | 49.18 | 46.68 | 62.47 |
Total Liabilities & Equity | 257.02 | 293.83 | 304.65 | 75.2 | 66.92 | 85.49 |
Total Debt | 33.76 | 29.03 | 8.24 | 9.08 | 10.56 | 5.56 |
Net Cash (Debt) | 202.69 | 250.22 | 277.74 | 48.46 | 40.76 | 70.51 |
Net Cash Growth | -14.01% | -9.91% | 473.08% | 18.91% | -42.20% | - |
Net Cash Per Share | 4.17 | 5.65 | 7.25 | 71.94 | 89.48 | 0.27 |
Book Value | 195.58 | 232.28 | 266.59 | -131.4 | -74 | -46.25 |
Book Value Per Share | 4.03 | 5.25 | 6.95 | -195.06 | -162.46 | -0.17 |
Tangible Book Value | 195.58 | 232.28 | 266.59 | -131.4 | -74 | -46.25 |
Tangible Book Value Per Share | 4.03 | 5.25 | 6.95 | -195.06 | -162.46 | -0.17 |